This research aims to evaluate the efficacy of topical delgocitinib in treating moderate to severe atopic hand eczema.
Randomized double-blind trial design
Participants with moderate to severe atopic hand eczema
Comparative analysis with dupilumab for efficacy
Delgocitinib significantly improved eczema severity scores compared to baseline (HR XX, 95% CI XX-XX, p=0.XX)
High rate of patient-reported improvement in daily activities, indicating enhanced quality of life
Abstract
Atopic hand eczema is a chronic irritating skin condition that impairs patients’ ability to perform daily tasks, affecting their jobs and mental well-being. Dupilumab has been revolutionary for ato...